Molecular profile and cell cycle in MCF-7 and MCF‑7/Dox cells exposed to conventional and liposomal forms of doxorubicin by Rusetskaya, N.V. et al.
140 Experimental Oncology 31, 140–143, 2009 (September)
Anthracyclines are widely used for treating breast 
cancer (BC). Nevertheless, their cardiotoxi city 
is a cause of serious concern. Moreover, the resis-
tance of the tumor to anthracyclines developed in the 
course of the treatment makes them inefficient for 
further therapy. Recently, it was suggested that both 
problems might be partially overcame using liposome-
encapsulated anthracyclines. Liposome-encapsulated 
anthracyclines differ from their free counterparts 
in many respects, e. g. the ways of target delivery, 
pharmacokinetics, distribution in organs and tissues, 
toxicity and efficacy [1, 2]. Several studies suggest 
the partial reversion of cytostatic resistance using 
liposomal forms of doxorubicin. That is why liposome-
encapsulated cytostatics are recommended for the 
treatment of the resistant forms of BC [3]. Meanwhile, 
we have not found out the data on the effects of lipo-
some-encapsulated anthracyclines in vitro in cells with 
resistance phenotype in the literature.
The aim of our study was to compare the effects 
of doxorubicin in conventional and liposomal forms 
on molecular profile and cell cycle of MCF-7 cells 
sensitive and resistant to doxorubicin. 
MATERIALS AND METHODS
Cell lines. For our studies, we used MCF-7 hu-
man BC cell line and its subline resistant to doxo-
rubicin — MCF-7/Dох. MCF-7 cells were cultured 
in Iscove’s Modified Dulbecco’s Medium (Sigma, Ger-
many) with 10% FBS (Sangva, Ukraine), at 37 °С and 
5% of СО2. The cells were reseeded twice a week 
with the density of 2–4 x 104 cells/cm2, when cell 
layer covered 50% of the flask surface. MCF-7/Dox 
subline was obtained by gro wing original MCF-7 cells 
with increasing concentrations of doxorubicin in the 
range from 0.1 to 32 μg/ml. Doxorubicin was added 
twice a week at each cell passage. Every two months, 
the cells were assayed for their resistance using MTT 
technique. IC50 (50% inhibition of cell growth) for 
MCF-7 and MCF-7/Dох cells were 0.5 and 8 μg/ml 
of doxorubicin respectively. Therefore, MCF-7/Dох 
cells were 16 times as much resistant to doxorubicin 
as compared with their initial counterpart.
МТТ-test. The sensitivity to doxorubicin and its 
liposomal form was assayed using standard МТТ-
coloremitric with 3-[4,5-dimethylthiasol-2–1]-2,5-
diphenyltetrasolium bromide produced by Sigma, 
Germany. MCF-7 and MCF-7/Dox cells were cultured 
with liposomal or conventional forms of doxorubicin 
in the dose range of 1–32 μg/ml for 24 h [4].
Immunocytochemical analysis. The expression 
of surface and intracellular antigens was examined 
using immunocytochemical method with monoclonal 
antibodies to P-glycoprotein (P-gp), estrogen recep-
tor (ER), progesterone receptor (PR), p53, Bcl-2, 
Е-cadherin, metallothioneins (MT), Кі-67, cycline D1, 
pRb, c-myc, p21 (Dako Сytomation, Denmark) in de-
scribed concentrations [5].
Flow cytometry. For the cell cycle analysis, cell 
suspension was washed and fixed on ice with 70% 
ethanol. Afterwards the samples were centrifugued 
at 300 х g for 5 min and the pellet was resuspended 
in 400 μl of physiological saline. 50 μl of RNAse and 
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10 μl of propidium iodide were added. The samples were 
analyzed on “Partec” flow cytometer (Germany) [6].
RESULTS AND DISCUSSION
Phenotypic patterns of sensitive and resistant 
MCF-7 cells exposed to conventional or liposome-
encapsulated doxorubicin. In our previous research, 
we have shown that the formation of doxorubicin resis-
tance phenotype in human ΜCF-7 cells was accompa-
nied by the changes in receptor status, cells adhesion 
properties and proliferation activity. We have also shown 
that the systems of metallothionein detoxication and 
ATP-dependent P-glycoprotein are directly involved 
in resistance to doxorubucine in MCF-7 cells [7].
The phenotypic patterns of MCF-7 cells and their 
resistant counterparts exposed to different forms 
doxorubicin are summarized in Fig. 1.
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Fig. 1. Phenotype of MCF-7 cells exposed to conventional 
or liposomal forms of doxorubicin. a, Initial MCF-7 cells. b, Doxo-
rubicin-resistant cells
Intracellular MT system is an important component 
of cell protection against cytostatic toxic effects. 
MT detoxifying effects are provided by their binding 
electrophylic anti-tumor cytostatics, as in free state 
MT are nucleophylic compounds [8, 9]. In our research, 
MT expression was detected in the majority (70%) 
of sensitive MCF-7 cells. The incubation of ΜCF-7 
sensitive cells with doxorubicin in conventional form 
decreased the amount of MT-positive cells by 50% 
while MT expression upon exposure to liposomal form 
of doxorubicin remained unchanged (Fig. 1, a). The 
development of resistance to doxorubicin was ac-
companied by the decrease of the MT expression level 
by 60% and the same low level of expression remained 
upon exposure of resistance cells to conventional or li-
posomal forms of doxorubicin (Fig. 1, b). Therefore, 
MT directly participates in detoxification of the free 
form of doxorubicin in sensitive MCF-7 cells. 
According to the data from numerous clinical 
observations [10], the absence of steroid receptor 
expression found in ⅓ of BC patients correlates with 
low sensitivity of tumors to anti-tumor therapy. Earlier 
we have shown that in MCF-7 cells resistant to doxo-
rubicin the level of ER and PR expression significantly 
dropped. Significant decrease of the expression level 
of steroid hormones receptors was observed upon 
culturing of original MCF-7 cells with doxorubicin 
in conventional form, while cultivation with its liposomal 
form did not trigger such changes (see Fig. 1, a). 
It is known that anti-tumor activity of the major-
ity of anti-tumor cytostatics is associated with induc-
tion of apoptosis in tumor cells. Therefore, we have 
attempted to analyze the expression of p53 as well 
as anti-apoptotic Bcl-2 protein in sensitive and resistant 
MCF-7 cells exposed to doxorubicin in conventional 
or liposomal form. The expression level of p53 protein 
in doxorubicin-resistant MCF-7 cells was practically the 
same as in the initial cell line. The exposure of ΜCF-
7 cells to doxorubicin in conventional form triggered 
the decrease of p53 expression and the increase of Bcl-
2 expression (see Fig. 1, a). Neither conventional nor 
liposomal form of doxorubicin altered Bcl-2 expression 
in doxorubicin-resistant ΜCF-7 cells (see Fig. 1, b).
Analysis of the expression profile of the above 
mentioned as well other studied proteins (Fig. 1, a, b) 
suggests that the most prominent effects of doxorubicin 
are evident mostly in the original cell line. The differential 
effects of the conventional and liposomal forms of this 
drug in sensitive and resistant cells are also evident. 
Analysis of cell cycle traverse in MCF-7 and 
MCF-7/Dox lines exposed to conventional or lipo-
some-encapsulated doxorubicin. It is known that 
the mechanism of doxorubicin activity is in DNA binding 
and inhibition of nucleic acids synthesis. Doxorubicin 
is a phase-specific anti-tumor drug with maximal sen-
sitivity demonstrated in S and G2 phases of cell cycle. 
It is worth noting that cell phase distribution in MCF-7 and 
MCF-7/Dox lines was practically identical (Table, Fig. 2, 
а, b). Previously we have shown that the changes in cell 
distribution over cell cycle phases in course of prolonged 
cultivation of MCF-7 and MCF-7/Dox cells with doxoru-
bicin and cysplatine were identical [7]. In our research, 
exposure of MCF-7 original line to doxorubicin in con-
ventional form for 24 h caused cell cycle arrest in G0/G1 
(Fig. 2, с). In contrast, conventional form of doxorubicin 
did not trigger changes in cell distribution over cell cycle 
phases of MCF-7/Dox cells in 24 h of cultivation (Fig. 2, 
d). Upon exposure of both sensitive and resistant lines 
to doxorubicin in liposomal form, cell cycle blockage 
in G0/G1 phase was observed (Table, Fig. 2, e, f). Such 
changes in cell distribution over cell cycle phases trig-
gered the changes in the level of expression of proteins 
regulating cell cycle. During arrest of cell cycle in G0/
G1 phase observed under the influence of conventional 
doxorubicin on MCF-7 cells and the influence of liposom-
al doxorubicin on MCF-7 and MCF-7/Dox sublines, the 
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simultaneous changes in the expression level of proteins 
regulating cell cycle took place. In particular, in MCF-
7 and MCF-7/Dox cells the decrease of cycline-D1, pRb 
and c-myc expression level was observed, as well as the 
increase of p21expession (see Fig. 1). According to the 
data described in the literature, the increase of p21 ex-
pression causes suppression of activity of cycline D-Cdk 
4,6 and cycline Е-Cdk 2 complexes and, as a result, cells 
are arrested in G0/G1 phase [11]. The changes in the ex-
pression levels of proteins regulating cell cycle upon the 
exposure to doxorubicin in conventional and liposomal 
forms suggest the decrease of cell proliferation activity 
(see Fig. 1, Table). 
Table. Cell cycle distribution of MCF-7 and MCF-7/Dox exposed 
to conventional or liposomal forms of doxorubicin
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G0/G1 55.11 70.4 69.19 61.05 64.93 77.51
S 28.85 11.93 20.79 27.25 20.55 7.6
G2/M 16.04 17.67 10.02 11.73 14.52 14.89
Thus, we have characterized the molecular profile 
and cell cycle traverse of sensitive and resistant human 
BC lines exposed to doxorubicin in conventional and li-
posomal forms. It was shown that the conventional form 
of doxorubicin triggers significant changes in original 
MCF-7 cells, namely the decrease in metallothioneins, 
p53 protein and steroid hormones receptors and the 
increased level of anti-apoptotic Bcl-2 protein. The 
culture of MCF-7 cells with doxorubicin in conventional 
form resulted in the arrest of cell cycle in G0/G1 phase 
with the accompanying changes in the level of proteins, 
regulating cell cycle and the decrease of cells prolif-
eration activity. In contrast, the exposure of MCF-7/
Dox resistant line to doxorubicin in conventional form 
does not trigger the changes of molecular profile. The 
distribution of cells over cell cycle phases remains 
identical to that in control sample. Culturing of the cells 
with liposomal form of the drug causes insignificant 
decrease of p53 expression level in MCF-7/Dox cells. 
Upon exposure to doxorubicin in liposomal form, the 
blockage of cell cycle in G0/G1 phase was observed 
800
640
480
320
160
0
0 100 200 300 400 500
Co
un
ts
FL3-PI
800
640
480
320
160
0
0 100 200 300 400 500
Co
un
ts
FL3-PI
800
640
480
320
160
0
0 100 200 300 400 500
Co
un
ts
FL3-PI
800
640
480
320
160
0
0 100 200 300 400 500
Co
un
ts
FL3-PI
800
640
480
320
160
0
0 100 200 300 400 500
Co
un
ts
FL3-PI
800
640
480
320
160
0
0 100 200 300 400 500
Co
un
ts
FL3-PI
a b
c d
fe
Fig. 2. Differences in cell cycle distribution in MCF-7 and MCF-7/Dox cells exposed to conventional or liposomal form of doxoru-
bicin. a, MCF-7; b, MCF-7/Dox cells; c, MCF-7 cells after exposure to conventional form of doxorubicin; d, MCF-7/Dox cells after 
exposure to conventional form of doxorubicin; e, MCF-7 cells after exposure to liposomal doxorubicin; f, MCF-7/Dox cells after 
exposure to liposomal doxorubicin
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in both sensitive and resistant cells. Therefore, we sug-
gest that the effects of doxorubicin in liposomal form 
are directly associated with the blockage of cell cycle 
of sensitive and resistant MCF-7 cells.
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